Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Belzutifan

NCT04924075

Merck · Phase 2 · Recruiting · Enrollment 355

NCT04924075

Catalyst Primary completion. 11.18.2032. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmReported safety

A count stays a count. This page does not turn a count into a percent.